Featured Article
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Bradley T. Hyman,
Creighton H. Phelps,
Thomas G. Beach,
Eileen H. Bigio,
Nigel J. Cairns,
Maria C. Carrillo,
Dennis W. Dickson,
Charles Duyckaerts,
Matthew P. Frosch,
Eliezer Masliah,
Suzanne S. Mirra,
Peter T. Nelson,
Julie A. Schneider,
Dietmar Rudolf Thal,
Bill Thies,
John Q. Trojanowski,
Harry V. Vinters,
Thomas J. Montine,
Bradley T. Hyman
Department of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA, USA
Search for more papers by this authorCreighton H. Phelps
National Institute on Aging, Bethesda, MD, USA
Search for more papers by this authorThomas G. Beach
Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA
Search for more papers by this authorEileen H. Bigio
Department of Pathology, Northwestern Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorNigel J. Cairns
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
Search for more papers by this authorDennis W. Dickson
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
Search for more papers by this authorCharles Duyckaerts
Service de Neuropathologie Raymond Escourolle, Hôpital de la Salpêtriére, Paris, France
Search for more papers by this authorMatthew P. Frosch
C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorEliezer Masliah
Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA
Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA
Search for more papers by this authorSuzanne S. Mirra
Department of Pathology, SUNY Downstate Medical Center, Brooklyn, NY, USA
Search for more papers by this authorPeter T. Nelson
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
Search for more papers by this authorJulie A. Schneider
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
Department of Pathology, Rush University Medical Center, Chicago, IL, USA
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Search for more papers by this authorDietmar Rudolf Thal
Institute of Pathology–Laboratory of Neuropathology, University of Ulm, Ulm, Germany
Search for more papers by this authorJohn Q. Trojanowski
Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Search for more papers by this authorHarry V. Vinters
Department of Pathology and Laboratory Medicine (Neuropathology), University of California Los Angeles, Los Angeles, CA
Department of Neurology, University of California Los Angeles, Los Angeles, CA
Search for more papers by this authorCorresponding Author
Thomas J. Montine
Department of Pathology, University of Washington School of Medicine, Seattle, WA
Corresponding author. Tel.: 206-543-1140; Fax: 206-897-5249.
E-mail address: [email protected]
Search for more papers by this author
Bradley T. Hyman,
Creighton H. Phelps,
Thomas G. Beach,
Eileen H. Bigio,
Nigel J. Cairns,
Maria C. Carrillo,
Dennis W. Dickson,
Charles Duyckaerts,
Matthew P. Frosch,
Eliezer Masliah,
Suzanne S. Mirra,
Peter T. Nelson,
Julie A. Schneider,
Dietmar Rudolf Thal,
Bill Thies,
John Q. Trojanowski,
Harry V. Vinters,
Thomas J. Montine,
Bradley T. Hyman
Department of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA, USA
Search for more papers by this authorCreighton H. Phelps
National Institute on Aging, Bethesda, MD, USA
Search for more papers by this authorThomas G. Beach
Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA
Search for more papers by this authorEileen H. Bigio
Department of Pathology, Northwestern Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorNigel J. Cairns
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
Search for more papers by this authorDennis W. Dickson
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
Search for more papers by this authorCharles Duyckaerts
Service de Neuropathologie Raymond Escourolle, Hôpital de la Salpêtriére, Paris, France
Search for more papers by this authorMatthew P. Frosch
C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Search for more papers by this authorEliezer Masliah
Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, USA
Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA
Search for more papers by this authorSuzanne S. Mirra
Department of Pathology, SUNY Downstate Medical Center, Brooklyn, NY, USA
Search for more papers by this authorPeter T. Nelson
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
Search for more papers by this authorJulie A. Schneider
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
Department of Pathology, Rush University Medical Center, Chicago, IL, USA
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Search for more papers by this authorDietmar Rudolf Thal
Institute of Pathology–Laboratory of Neuropathology, University of Ulm, Ulm, Germany
Search for more papers by this authorJohn Q. Trojanowski
Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Search for more papers by this authorHarry V. Vinters
Department of Pathology and Laboratory Medicine (Neuropathology), University of California Los Angeles, Los Angeles, CA
Department of Neurology, University of California Los Angeles, Los Angeles, CA
Search for more papers by this authorCorresponding Author
Thomas J. Montine
Department of Pathology, University of Washington School of Medicine, Seattle, WA
Corresponding author. Tel.: 206-543-1140; Fax: 206-897-5249.
E-mail address: [email protected]
Search for more papers by this authorAbstract
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre-clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP-43 inclusions, and recommend standard approaches for the workup of cases and their clinico-pathologic correlation.
References
- 1BT Hyman, JQ Trojanowski. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 56: 1997; 1095–1097
- 2MS Albert, ST Dekosky, D Dickson, B Dubois, HH Feldman, NC Fox, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 2011; 270–279
- 3RA Sperling, PS Aisen, LA Beckett, DA Bennett, S Craft, AM Fagan, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 2011; 280–292
- 4H Crystal, D Dickson, P Fuld, D Masur, R Scott, M Mehler, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 38: 1988; 1682–1687
- 5JL Price, DW McKeelJr., VD Buckles, CM Roe, C Xiong, M Grundman, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 30: 2009; 1026–1036
- 6RJ Caselli, D Walker, L Sue, M Sabbagh, T Beach. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett. 473: 2010; 168–171
- 7TG Beach, YM Kuo, K Spiegel, MR Emmerling, LI Sue, K Kokjohn, et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol. 59: 2000; 308–313
- 8PE Potter, PK Rauschkolb, Y Pandya, LI Sue, MN Sabbagh, DG Walker, et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol. 122: 2011; 49–60
- 9TG Beach, WG Honer, LH Hughes. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?. Acta Neuropathol. 93: 1997; 146–153
- 10HA Crystal, DW Dickson, MJ Sliwinski, RB Lipton, E Grober, H Marks-Nelson, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol. 34: 1993; 566–573
- 11DW Dickson, HA Crystal, LA Mattiace, DM Masur, AD Blau, P Davies, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 13: 1992; 179–189
- 12C Bouras, PR Hof, P Giannakopoulos, JP Michel, JH Morrison. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex. 4: 1994; 138–150
- 13H Braak, E Braak. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 18: 1997; 351–357
- 14JL Price, JC Morris. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol. 45: 1999; 358–368
- 15FA Schmitt, DG Davis, DR Wekstein, CD Smith, JW Ashford, WR Markesbery. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 55: 2000; 370–376
- 16L Davies, B Wolska, C Hilbich, G Multhaup, R Martins, G Simms, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 38: 1988; 1688–1693
- 17DA Bennett, JA Schneider, RS Wilson, JL Bienias, SE Arnold. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 61: 2004; 378–384
- 18GM McKhann, DS Knopman, H Chertkow, BT Hyman, CR JackJr., CH Kawas, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 2011; 263–269
- 19H Braak, I Alafuzoff, T Arzberger, H Kretzschmar, K Del Tredici. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112: 2006; 389–404
- 20H Braak, E Braak. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82: 1991; 239–259
- 21SS Mirra, A Heyman, D McKeel, SM Sumi, BJ Crain, LM Brownlee, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41: 1991; 479–486
- 22DW Dickson. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 56: 1997; 321–339
- 23DR Thal, U Rub, M Orantes, H Braak. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 58: 2002; 1791–1800
- 24DR Thal, U Rub, C Schultz, I Sassin, E Ghebremedhin, K Del Tredici, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 59: 2000; 733–748
- 25JP Vonsattel, RH Myers, ET Hedley-Whyte, AH Ropper, ED Bird, EP RichardsonJr.. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 30: 1991; 637–649
- 26DR Thal, WS Griffin, RA de Vos, E Ghebremedhin. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 115: 2008; 599–609
- 27PT Nelson, EL Abner, FA Schmitt, RJ Kryscio, GA Jicha, K Santacruz, et al. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol. 68: 2009; 774–784
- 28H Braak, K Del Tredici. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121: 2011; 171–181
- 29H Braak, DR Thal, E Ghebremedhin, K Del Tredici. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 70: 2011; 960–969
- 30Z Nagy, DM Yilmazer-Hanke, H Braak, E Braak, C Schultz, J Hanke. Assessment of the pathological stages of Alzheimer's disease in thin paraffin sections: a comparative study. Dement Geriatr Cogn Disord. 9: 1998; 140–144
- 31I Alafuzoff, T Arzberger, S Al-Sarraj, I Bodi, N Bogdanovic, H Braak, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 18: 2008; 484–496
- 32R Crook, A Verkkoniemi, J Perez-Tur, N Mehta, M Baker, H Houlden, et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 4: 1998; 452–455
- 33DM Walsh, DJ Selkoe. A beta oligomers—a decade of discovery. J Neurochem. 101: 2007; 1172–1184
- 34E Masliah, RD Terry, M Mallory, M Alford, LA Hansen. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol. 137: 1990; 1293–1297
- 35E Masliah, M Mallory, T Deerinck, R DeTeresa, S Lamont, A Miller, et al. Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. J Neuropathol Exp Neurol. 52: 1993; 619–632
- 36RD Terry, E Masliah, DP Salmon, N Butters, R DeTeresa, R Hill, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 30: 1991; 572–580
- 37ST DeKosky, SW Scheff. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 27: 1990; 457–464
- 38I Alafuzoff, DR Thal, T Arzberger, N Bogdanovic, S Al-Sarraj, I Bodi, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 117: 2009; 309–320
- 39JC Morris. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 43: 1993; 2412–2414
- 40TJ Montine, EB Larson. Late-life dementias: does this unyielding global challenge require a broader view?. JAMA. 302: 2009; 2593–2594
- 41PT Nelson, EL Abner, FA Schmitt, RJ Kryscio, GA Jicha, CD Smith, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 20: 2010; 66–79
- 42TG Beach, CL White, RL Hamilton, JE Duda, T Iwatsubo, DW Dickson, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 116: 2008; 277–288
- 43I Alafuzoff, L Parkkinen, S Al-Sarraj, T Arzberger, J Bell, I Bodi, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 67: 2008; 125–143
- 44I Alafuzoff, M Pikkarainen, S Al-Sarraj, T Arzberger, J Bell, I Bodi, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 65: 2006; 740–757
- 45IG McKeith, DW Dickson, J Lowe, M Emre, JT O'Brien, H Feldman, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 65: 2005; 1863–1872
- 46Y Saito, NN Ruberu, M Sawabe, T Arai, H Kazama, T Hosoi, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol. 63: 2004; 742–749
- 47CH Adler, DJ Connor, JG Hentz, MN Sabbagh, JN Caviness, HA Shill, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 25: 2010; 642–646
- 48DW Dickson, H Fujishiro, A DelleDonne, J Menke, Z Ahmed, KJ Klos, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115: 2008; 437–444
- 49TG Beach, CH Adler, LI Sue, JB Peirce, J Bachalakuri, JE Dalsing-Hernandez, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115: 2008; 445–451
- 50GA Jicha, FA Schmitt, E Abner, PT Nelson, GE Cooper, CD Smith, et al. Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging. 31: 2010; 1805–1813
- 51WR Markesbery, GA Jicha, H Liu, FA Schmitt. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. 68: 2009; 816–822
- 52H Uchikado, WL Lin, MW DeLucia, DW Dickson. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 65: 2006; 685–697
- 53TG Beach, CH Adler, L Lue, LI Sue, J Bachalakuri, J Henry-Watson, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117: 2009; 613–634
- 54PT Nelson, RJ Kryscio, GA Jicha, EL Abner, FA Schmitt, LO Xu, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology. 73: 2009; 1127–1133
- 55RL Hamilton. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10: 2000; 378–384
- 56CF Lippa, JE Duda, M Grossman, HI Hurtig, D Aarsland, BF Boeve, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 68: 2007; 812–819
- 57JB Leverenz, MA Fishel, ER Peskind, TJ Montine, D Nochlin, E Steinbart, et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol. 63: 2006; 370–376
- 58O Pletnikova, N West, MK Lee, GL Rudow, RL Skolasky, TM Dawson, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging. 26: 2005; 1183–1192
- 59G Halliday, M Hely, W Reid, J Morris. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115: 2008; 409–415
- 60H Braak, K Del Tredici, U Rub, RA de Vos, EN Jansen Steur, E Braak. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 24: 2003; 197–211
- 61TG Beach, CL White3rd, CL Hladik, MN Sabbagh, DJ Connor, HA Shill, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 117: 2009; 169–174
- 62K Del Tredici, U Rub, RA De Vos, JR Bohl, H Braak. Where does Parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol. 61: 2002; 413–426
- 63OA Selnes, HV Vinters. Vascular cognitive impairment. Nat Clin Pract Neurol. 2: 2006; 538–547
- 64TG Beach, JR Wilson, LI Sue, A Newell, M Poston, R Cisneros, et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. 113: 2007; 13–21
- 65L White. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 18: 2009; 713–725
- 66JA Sonnen, EB Larson, PK Crane, S Haneuse, G Li, GD Schellenberg, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 62: 2007; 406–413
- 67PB Gorelick, A Scuteri, SE Black, C Decarli, SM Greenberg, C Iadecola, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 42: 2011; 2672–2713
- 68M Gearing, SS Mirra, JC Hedreen, SM Sumi, LA Hansen, A Heyman. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology. 45: 1995; 461–466
- 69PT Nelson, GA Jicha, FA Schmitt, H Liu, DG Davis, MS Mendiondo, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol. 66: 2007; 1136–1146
- 70HC Chui, C Zarow, WJ Mack, WG Ellis, L Zheng, WJ Jagust, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol. 60: 2006; 677–687
- 71JA Schneider, Z Arvanitakis, SE Leurgans, DA Bennett. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 66: 2009; 200–208
- 72JA Schneider, DA Bennett. Where vascular meets neurodegenerative disease. Stroke. 41: 2010; S144–S146
- 73RS Wilson, SE Leurgans, PA Boyle, JA Schneider, DA Bennett. Neurodegenerative basis of age-related cognitive decline. Neurology. 75: 2010; 1070–1078
- 74V Hachinski, C Iadecola, RC Petersen, MM Breteler, DL Nyenhuis, SE Black, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 37: 2006; 2220–2241
- 75JA Sonnen, EB Larson, S Haneuse, R Woltjer, G Li, PK Crane, et al. Neuropathology in the adult changes in thought study: a review. J Alzheimers Dis. 18: 2009; 703–711
- 76HV Vinters. Cerebral amyloid angiopathy. A critical review. Stroke. 18: 1987; 311–324
- 77HV Vinters, WG Ellis, C Zarow, BW Zaias, WJ Jagust, WJ Mack, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 59: 2000; 931–945
- 78LT Grinberg, DR Thal. Vascular pathology in the aged human brain. Acta Neuropathol. 119: 2010; 277–290
- 79HV Vinters. Cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia?. Ann Neurol. 49: 2001; 691–693
- 80HV Vinters. Cerebral amyloid angiopathy and Alzheimer's disease: two entities or one?. J Neurol Sci. 112: 1992; 1–3
- 81JA Sonnen, EB Larson, K Brickell, PK Crane, R Woltjer, TJ Montine, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol. 66: 2009; 315–322
- 82V Soontornniyomkij, MD Lynch, S Mermash, J Pomakian, H Badkoobehi, R Clare, et al. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol. 20: 2010; 459–467
- 83C Amador-Ortiz, DW Dickson. Neuropathology of hippocampal sclerosis. Handb Clin Neurol. 89: 2008; 569–572
- 84PT Nelson, FA Schmitt, Y Lin, EL Abner, GA Jicha, E Patel, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 134: 2011; 1506–1518
- 85KJ Hatanpaa, DM Blass, O Pletnikova, BJ Crain, EH Bigio, JC Hedreen, et al. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology. 63: 2004; 538–542
- 86C Amador-Ortiz, WL Lin, Z Ahmed, D Personett, P Davies, R Duara, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 61: 2007; 435–445
- 87Y Miki, F Mori, E Hori, M Kaimori, K Wakabayashi. Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol. 117: 2009; 713–718
- 88EB Lee, VM Lee, JQ Trojanowski, M Neumann. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 115: 2008; 305–311
- 89T Arai, IR Mackenzie, M Hasegawa, T Nonoka, K Niizato, K Tsuchiya, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 117: 2009; 125–136
- 90H Nakashima-Yasuda, K Uryu, J Robinson, SX Xie, H Hurtig, JE Duda, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 114: 2007; 221–229
- 91AC Wilson, BN Dugger, DW Dickson, DS Wang. TDP-43 in aging and Alzheimer's disease—a review. Int J Clin Exp Pathol. 4: 2011; 147–155
- 92IR Mackenzie, M Neumann, EH Bigio, NJ Cairns, I Alafuzoff, J Kril, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119: 2010; 1–4
- 93IR Mackenzie, M Neumann, EH Bigio, NJ Cairns, I Alafuzoff, J Kril, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 117: 2009; 15–18
- 94NJ Cairns, EH Bigio, IR Mackenzie, M Neumann, VM Lee, KJ Hatanpaa, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114: 2007; 5–22
- 95KA Jellinger, C Bancher. Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol. 8: 1998; 367–376
- 96ML Schmidt, V Zhukareva, KL Newell, VM Lee, JQ Trojanowski. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol. 101: 2001; 518–524
- 97K Kosaka. Diffuse neurofibrillary tangles with calcification: a new presenile dementia. J Neurol Neurosurg Psychiatry. 57: 1994; 594–596
- 98T Uchihara, A Nakamura, M Yamazaki, O Mori, K Ikeda, K Tsuchiya. Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method. Acta Neuropathol. 102: 2001; 462–466
- 99SR Dlouhy, K Hsiao, MR Farlow, T Foroud, PM Conneally, P Johnson, et al. Linkage of the Indiana kindred of Gerstmann-Straussler-Scheinker disease to the prion protein gene. Nat Genet. 1: 1992; 64–67
- 100CR JackJr., DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9: 2010; 119–128
- 101S Seshadri, AL Fitzpatrick, MA Ikram, AL DeStefano, V Gudnason, M Boada, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 303: 2010; 1832–1840
- 102AC Naj, G Jun, GW Beecham, LS Wang, BN Vardarajan, J Buros, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 43: 2011; 436–441
- 103KJ Anstey, N Cherbuin, M Budge, J Young. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 12: 2011; e426–e437
- 104RC Ho, MW Cheung, E Fu, HH Win, MH Zaw, A Ng, et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 19: 2011; 607–617
- 105MC Power, J Weuve, JJ Gagne, MB McQueen, A Viswanathan, D Blacker. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 22: 2011; 646–659
- 106JB Leverenz, R Hamilton, DW Tsuang, A Schantz, D Vavrek, EB Larson, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 18: 2008; 220–224
